IR-MED’s PressureSafe™ Reduced Pressure Injuries by 50% During a Usability Study with Clalit, Israel’s Largest HMO Poster presentation available here: LINK Rosh Pina, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- IR-MED Inc., (“IR-MED” or the “Company”) (OTCQB:IRME), developer of a noninvasive artificial...

IR-MED’s PressureSafe™ Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries Marks major milestone prior to launch in U.S. marketPressureSafe™ scanner and disposable pack both listed with FDAPressureSafe™ can support early detection of pressure injuries, potentially setting a...

IR-MED Reports 92% Efficacy for PressureSafe™ in Early, Non-Invasive, Skin Color Agnostic Detection of Pressure Injuries Incidence of pressure injuries reduced by 50% during the study periodAs a decision support device, PressureSafe, can support early detection of pressure injuries, potentially setting a new standard of...

IR-MED Granted Patent in Israel for its AI-Driven Platform Technology: Non-Invasive Analysis of Subcutaneous Tissue The Granted patent covers IR-MED’s PressureSafe™ decision support device for the early detection of pressure injuries addressing a healthcare burden that amounts to $26.8 billion in the U.S. annually...

IR-MED Appoints Richard Serbin, Esq. to its Advisory Board Served as Chief FDA Counsel for Revlon and Johnson & Johnson, as a Board Member at Johnson & Johnson Development Corporation, that company’s strategic venture capital division, and as patent...